| Literature DB >> 31690044 |
Suryaji Patil1,2,3, Yong-Guang Gao4,5,6, Xiao Lin7,8,9, Yu Li10,11,12, Kai Dang13,14,15, Ye Tian16,17,18, Wen-Juan Zhang19,20,21, Shan-Feng Jiang22,23,24, Abdul Qadir25,26,27, Ai-Rong Qian28,29,30.
Abstract
Gene therapy is manipulation in/of gene expression in specific cells/tissue to treat diseases. This manipulation is carried out by introducing exogenous nucleic acids, such as DNA or RNA, into the cell. Because of their negative charge and considerable larger size, the delivery of these molecules, in general, should be mediated by gene vectors. Non-viral vectors, as promising delivery systems, have received considerable attention due to their low cytotoxicity and non-immunogenicity. As research continued, more and more functional non-viral vectors have emerged. They not only have the ability to deliver a gene into the cells but also have other functions, such as the performance of fluorescence imaging, which aids in monitoring their progress, targeted delivery, and biodegradation. Recently, many reviews related to non-viral vectors, such as polymers and cationic lipids, have been reported. However, there are few reviews regarding functional non-viral vectors. This review summarizes the common functional non-viral vectors developed in the last ten years and their potential applications in the future. The transfection efficiency and the transport mechanism of these materials were also discussed in detail. We hope that this review can help researchers design more new high-efficiency and low-toxicity multifunctional non-viral vectors, and further accelerate the progress of gene therapy.Entities:
Keywords: biodegradation; fluorescent imaging; functional non-viral vectors; gene therapy; targeted delivery
Mesh:
Year: 2019 PMID: 31690044 PMCID: PMC6862238 DOI: 10.3390/ijms20215491
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Advantages and disadvantages of viral vectors [9].
| Vectors | Virus | Advantages | Disadvantages |
|---|---|---|---|
| Viral | Retrovirus | Long-term gene expression | Low efficiency in vivo, immunogenic problems, the inability to transduce the nondividing cells, and the risk of insertion, infects dividing cells only. |
| Lentivirus | Long-term gene expression, infects non-dividing and dividing cells | Generation of replication-competent virus, Potential for tumorigenesis | |
| Vaccinia virus | High immunogenicity safety: used as a smallpox vaccine, high titer production | Pre-existing immunity | |
| Adenovirus | Transfect dividing and non-dividing cells and have low host specificity, deliver large DNA particles (up to 38 kb), high immunogenicity safety: used in many clinic trails, high titer production | Gene expression is too short term, pre-existing immunity. | |
| Adeno-associated virus | Long-term gene expression, non-pathogenic virus | Low titer production | |
| Cytomegalovirus | Induces a unique CTL response, protects against SIV infection in an animal model | Pre-existing immunity risk of pathogenesis in specific individuals |
Figure 1Advantages of non-viral vectors.
Figure 2The structures of cationic lipids.
Figure 3Basic mechanism of non-viral gene delivery via polyplex and lipoplex.
Liposome-mediated clinical trials for cancer gene therapy [40].
| Cancer | Major Carrier | Gene | Administration Route | Phase (Start Year) | Note |
|---|---|---|---|---|---|
| Stage IV melanoma | DC-Chol | HLA-B7 | Intratumoral, Intrapulmonaty | Phase I (1993) | |
| Head and neck cancer | DC-Chol | EGFR antisense | Intratumoral | Phase I (1999) | |
| Head and neck cancer, breast cancer, | DC-Chol | E1A | Intratumoral with catheter | Phase I (1999) | |
| Breast cancer, ovarian cancer | DC-Chol | E1A | Intrapleural, Intraperitoneal | Phase I (1999) | |
| Ovarian cancer | DC-Chol | E1A | Intraperitoneal | Phase I/II (2004) | tgDCC-E1A in combination with paclitaxel |
| Head and neck cancer | DC-Chol | E1A | Intratumoral | Phase II (2002) | tgDCC-E1A |
| Metastatic melanoma | DMRIE | HLA-B7/β2-microglobulin | Intratumoral | Phase I (1997) | |
| Metastatic melanoma | DMRIE | HLA-B7/β2-microglobulin | Intratumoral | Phase II (2002) | Allovectin-7 alone |
| Stage 3 or Stage 4 melanoma | DMRIE | HLA-B7/β2-micrOglobulin | Intratumoral | Phase III (2006) | Allovectin-7 alone compared with chemotherapy |
| Head and neck cancer | DMRIE | HLA-B7 | Intratumoral | Phase I (2001) Phase II 2002) | Allovectin-7 |
| Prostate cancer | DMRIE | IL-2 | Intraprostatiscal | Phase I/II (2000) | Leuvectin |
| Leukemia | DOTIM | Non-coding plasmid DNA | Vaccination | Phase I (2009) | As an adjuvant (JVRS-100) |
| Advanced solid tumor, advanced malignancy | Cationic cardiolipin | c-raf antisense | Intravenous | Phase I (2004) | LErafAON-ETU |
| Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome | Unknown | L-Grb-2 antisense | Intravenous | Phase I (2010) |
DC-Chol-: 3beta-[N-(N′,N′-Dimethylaminoethane)-carbamoyl]cholesterol, DMRIE-: 1,2-dimyristyloxy-propyl-3-dimethyl-hydroxy ethyl ammonium bromide, DOTIM-: 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride.
Figure 4The structures of polymers.
Figure 5Schematic illustration of G2-AuNP/β-gal-siRNA complexation and transfection into SVR-bag4 cells [32].
Figure 6Various methods to enhance nuclear localization [64] (Reprinted by permission from Springer Nature and Copyright Clearance Center: Springer Nature, Gene Therapy, Nuclear entry of nonviral vectors, D A Dean et al. 2005.).
Figure 7Linker mediated mitochondrial transport [72].
Figure 8Schematic of SDSSD based delivery system.
Figure 9Schematic illustration for the synthesis of GOPEI-AuNPs and GOPEI-AuNRs and the possible mechanism of gene delivery using GOPEI-AuNPs as a carrier.